Project profile — COVID-19 Vaccine Research and Development

This project aims to support the Coalition for Epidemic Preparedness Innovations (CEPI) in developing, manufacturing, and distributing up to 1.2 billion doses of COVID-19 vaccine(s) and other emerging infectious diseases. This is done through a fair allocation system within 12 to 18 months prioritizing speed, scale, and access. Project activities include: (1) supporting the research and development of up to 5 vaccine candidates; and (2) supporting the manufacture and distribution of up to 1.2 billion vaccine doses by 2021. This amendment increased Canada’s original contribution under this project to CEPI by $20 Million.

The expected outcomes of this project include: (1) strengthened global preparedness for known epidemic and pandemic threats; (2) strengthened global response to emerging pandemic threats; and (3) improved collaboration between public and private pandemic preparedness and response stakeholders.

Results achieved as of 24 May 2022 include: (1) developed 8 COVID-19 vaccine candidates with CEPI support. 7 out of the 8 progressed into Phase II and III clinical trials; (2) supported 3 COVID-19 vaccine candidates (Moderna, Astra Zeneca and Novavax) to receive authorization for emergency use by the World Health Organization (WHO); (3) supported 5 candidates to publish primary endpoint analysis of pivotal trial (AZ/Uni Oxford, Moderna, Novavax, CureVac and Clover); and (4) delivered over 900 million COVID-19 vaccine doses in 2021, reaching 95% of its target.